Yaiza García-Ramírez, Juana-María Cayuela-Fuentes, María-Pilar Mira-Escolano, Luis-Alberto Maceda-Roldán, Eva Mikulasova, Cristina Oliva-López, Antonia Sánchez-Escámez, Pilar Ciller-Montoya, Joaquín A Palomar-Rodríguez
{"title":"2008-2021年西班牙东南部肌萎缩性侧索硬化症患者的特征、流行病学和相关进化和生存因素:一项基于人群的研究","authors":"Yaiza García-Ramírez, Juana-María Cayuela-Fuentes, María-Pilar Mira-Escolano, Luis-Alberto Maceda-Roldán, Eva Mikulasova, Cristina Oliva-López, Antonia Sánchez-Escámez, Pilar Ciller-Montoya, Joaquín A Palomar-Rodríguez","doi":"10.1080/21678421.2024.2439454","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To describe the epidemiology, characteristics, and factors associated with the evolution and survival in patients with amyotrophic lateral sclerosis (ALS) in a region of southeastern Spain.</p><p><strong>Methods: </strong>An observational study was carried out in people with a diagnosis of ALS in the period 2008-2021 who were registered in the Information System of Rare Diseases of the Region of Murcia (SIER). We calculated crude and standardized incidence rate (SIR) using European Standard Population of 2013 and point prevalence. The Kaplan-Meier method and the log-rank test were used to estimate and compare survival curves.</p><p><strong>Results: </strong>We identified 374 cases. The mean age at diagnosis was 66.5 ± 11.7 and 50.3% persons were spinal onset. Mean time from the onset of symptoms to diagnosis was 0.9 ± 1.0 years. The global SIR was 1.95/100,000 person-years (95%CI: 1.77-2.12), which was higher in men (ratio 1.34), and the point prevalence in 2021 was 4.57 per 100,000 (95% CI: 4.46-4.68). There were 297 deaths with a mean age of 69.8 ± 10.8. The median survival from clinical onset was 2 years (95%CI: 1.0-3.0). Factors associated with lower survival were bulbar onset (<i>p</i> < 0.001), older age at the onset of symptoms (<i>p</i> < 0.001), and the absence of riluzole treatment (<i>p</i> = 0.003).</p><p><strong>Conclusions: </strong>This study is one of few to evaluate the epidemiological, characteristics, and prognostic factors of ALS in Spain, with findings similar to previous population studies. The use of population-based registries offers reliable information on the magnitude, or evolution in these patients.</p>","PeriodicalId":72184,"journal":{"name":"Amyotrophic lateral sclerosis & frontotemporal degeneration","volume":" ","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterization, epidemiology, and factors associated with evolution and survival in patients with amyotrophic lateral sclerosis in southeastern Spain, 2008-2021: a population-based study.\",\"authors\":\"Yaiza García-Ramírez, Juana-María Cayuela-Fuentes, María-Pilar Mira-Escolano, Luis-Alberto Maceda-Roldán, Eva Mikulasova, Cristina Oliva-López, Antonia Sánchez-Escámez, Pilar Ciller-Montoya, Joaquín A Palomar-Rodríguez\",\"doi\":\"10.1080/21678421.2024.2439454\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To describe the epidemiology, characteristics, and factors associated with the evolution and survival in patients with amyotrophic lateral sclerosis (ALS) in a region of southeastern Spain.</p><p><strong>Methods: </strong>An observational study was carried out in people with a diagnosis of ALS in the period 2008-2021 who were registered in the Information System of Rare Diseases of the Region of Murcia (SIER). We calculated crude and standardized incidence rate (SIR) using European Standard Population of 2013 and point prevalence. The Kaplan-Meier method and the log-rank test were used to estimate and compare survival curves.</p><p><strong>Results: </strong>We identified 374 cases. The mean age at diagnosis was 66.5 ± 11.7 and 50.3% persons were spinal onset. Mean time from the onset of symptoms to diagnosis was 0.9 ± 1.0 years. The global SIR was 1.95/100,000 person-years (95%CI: 1.77-2.12), which was higher in men (ratio 1.34), and the point prevalence in 2021 was 4.57 per 100,000 (95% CI: 4.46-4.68). There were 297 deaths with a mean age of 69.8 ± 10.8. The median survival from clinical onset was 2 years (95%CI: 1.0-3.0). Factors associated with lower survival were bulbar onset (<i>p</i> < 0.001), older age at the onset of symptoms (<i>p</i> < 0.001), and the absence of riluzole treatment (<i>p</i> = 0.003).</p><p><strong>Conclusions: </strong>This study is one of few to evaluate the epidemiological, characteristics, and prognostic factors of ALS in Spain, with findings similar to previous population studies. The use of population-based registries offers reliable information on the magnitude, or evolution in these patients.</p>\",\"PeriodicalId\":72184,\"journal\":{\"name\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"volume\":\" \",\"pages\":\"1-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic lateral sclerosis & frontotemporal degeneration\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2024.2439454\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic lateral sclerosis & frontotemporal degeneration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21678421.2024.2439454","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:描述西班牙东南部地区肌萎缩性侧索硬化症(ALS)患者的流行病学、特征以及与发展和生存相关的因素。方法:对在穆尔西亚地区罕见疾病信息系统(SIER)中登记的2008-2021年诊断为ALS的患者进行观察性研究。我们使用2013年欧洲标准人口和点患病率计算粗发病率和标准化发病率(SIR)。采用Kaplan-Meier法和log-rank检验估计和比较生存曲线。结果:共发现374例。平均诊断年龄为66.5±11.7岁,50.3%为脊柱起病。从症状出现到诊断的平均时间为0.9±1.0年。全球SIR为1.95/100,000人年(95%CI: 1.77-2.12),其中男性更高(比率1.34),2021年的点患病率为4.57 /100,000人年(95%CI: 4.46-4.68)。死亡297例,平均年龄(69.8±10.8)岁。从临床发病开始的中位生存期为2年(95%CI: 1.0-3.0)。与较低生存率相关的因素是球部发病(p p p = 0.003)。结论:本研究是少数评估西班牙ALS流行病学、特征和预后因素的研究之一,研究结果与以往的人群研究相似。以人群为基础的登记处的使用提供了关于这些患者的程度或演变的可靠信息。
Characterization, epidemiology, and factors associated with evolution and survival in patients with amyotrophic lateral sclerosis in southeastern Spain, 2008-2021: a population-based study.
Objective: To describe the epidemiology, characteristics, and factors associated with the evolution and survival in patients with amyotrophic lateral sclerosis (ALS) in a region of southeastern Spain.
Methods: An observational study was carried out in people with a diagnosis of ALS in the period 2008-2021 who were registered in the Information System of Rare Diseases of the Region of Murcia (SIER). We calculated crude and standardized incidence rate (SIR) using European Standard Population of 2013 and point prevalence. The Kaplan-Meier method and the log-rank test were used to estimate and compare survival curves.
Results: We identified 374 cases. The mean age at diagnosis was 66.5 ± 11.7 and 50.3% persons were spinal onset. Mean time from the onset of symptoms to diagnosis was 0.9 ± 1.0 years. The global SIR was 1.95/100,000 person-years (95%CI: 1.77-2.12), which was higher in men (ratio 1.34), and the point prevalence in 2021 was 4.57 per 100,000 (95% CI: 4.46-4.68). There were 297 deaths with a mean age of 69.8 ± 10.8. The median survival from clinical onset was 2 years (95%CI: 1.0-3.0). Factors associated with lower survival were bulbar onset (p < 0.001), older age at the onset of symptoms (p < 0.001), and the absence of riluzole treatment (p = 0.003).
Conclusions: This study is one of few to evaluate the epidemiological, characteristics, and prognostic factors of ALS in Spain, with findings similar to previous population studies. The use of population-based registries offers reliable information on the magnitude, or evolution in these patients.